Related Experiment Video
Updated: Oct 31, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer
Luis Javier Martínez-González1, Victor Sánchez-Conde2, Jose María González-Cabezuelo3
1GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada-Avenida de la Ilustración, 114-18016 Granada, Spain.
Abstract:
MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways' AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs' expression patterns, such as miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs' analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D'Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR-93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR-93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.
Insights
Specific microRNAs (miRNAs) show promise as biomarkers for prostate cancer (PC) diagnosis and risk stratification. MiR-93-5p is highlighted as a potential non-invasive biomarker for PC management.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) regulate key pathways in prostate cancer (PC), including androgen receptor signaling, cell cycle, apoptosis, and metastasis.
- Dysregulation of specific miRNAs is implicated in PC progression and aggressiveness.
Purpose of the Study:
- To investigate the expression patterns of specific miRNAs in prostate cancer tissues and plasma.
- To identify potential miRNA biomarkers for PC diagnosis, aggressiveness, and risk stratification.
Main Methods:
- miRNA expression analysis was performed on 159 PC fresh tissues and 60 peripheral blood plasma samples using Trizol extraction and TaqMan probes.
- Clinical data (PSA, Gleason, TNM, D'Amico risk) were collected for all samples.
- Bioinformatic analysis of miRNA expression in an extensive cohort (n=531) from The Cancer Genome Atlas (TCGA) was conducted.
Main Results:
- miR-210-3p, miR-23c, miR-592, and miR-93-5p were identified as potential biomarkers for PC aggressiveness and diagnosis.
- miR-93-5p demonstrated significant potential as a non-invasive biomarker for PC.
- These miRNAs are associated with processes such as cell proliferation and epithelial-to-mesenchymal transition (MET).
Conclusions:
- miR-210-3p, miR-23c, miR-592, and miR-93-5p are suggested as potential biomarkers for prostate cancer risk stratification.
- These miRNAs could be incorporated into non-invasive strategies like liquid biopsy for precision medicine in PC management.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs